AVN-322

AVN-322 is a selective antagonist of the 5-HT6 receptor that is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and schizophrenia. It is in the preclinical stage of development and has not yet been tested in humans.

Pharmacology

AVN-322 is a highly selective and potent antagonist of the 5-HT6 receptor. It has a Ki value of 0.38 nM for the 5-HT6 receptor and is more than 1,000-fold selective for the 5-HT6 receptor over all other receptors tested. AVN-322 has been found to improve cognition in animal models of Alzheimer's disease and schizophrenia.

Chemistry

AVN-322 is a small molecule that is structurally related to other 5-HT6 receptor antagonists like SB-399885, SB-271046, and SB-742457.

Development

AVN-322 is being developed by Avineuro Pharmaceuticals, a pharmaceutical company that specializes in the development of small molecule drugs for the treatment of neurological and psychiatric disorders. The drug is in the preclinical stage of development and has not yet been tested in humans.

See also

• 5-HT6 receptor
• Alzheimer's disease
• Schizophrenia
• Avineuro Pharmaceuticals

AVN-322 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski